News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immune Design Corporation Snags $212M Deal With MedImmune To Provide Vaccine Booster



10/26/2010 7:59:50 AM

>

SEATTLE, Oct. 26 /PRNewswire/ -- Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has entered into a license and development agreement with MedImmune for the use and commercialization of IDCs proprietary Glucopyranosyl Lipid Adjuvant (GLA) as a component in vaccines for select infectious diseases.

"We are pleased to enter into this license with MedImmune as one of the world's leading vaccine research-based pharmaceutical and healthcare companies," commented IDC Executive Chairman Dr. Bruce Carter. "This relationship fits very well with IDCs business model to advance the development of GLA and enable innovative vaccine products that we believe will provide significant benefit in areas of unmet need while maintaining our commitment to global access."

Under the terms of the license agreement, IDC grants MedImmune exclusive worldwide rights to research, develop, use, and commercialize the GLA adjuvant in vaccines for specific indications. In return, IDC will receive an upfront licensing fee and potential development, regulatory and commercial milestones totaling $212M, in addition to royalty payments on sales of marketed products.

GLA is a toll-like receptor 4 (TLR-4) agonist which IDC has advanced into early clinical stage development. The small molecule adjuvant has several important features including a pure synthetic composition with straightforward manufacturing and long term stability, a rational design for optimal activation of human dendritic cells, compatibility with antigens in multiple formulations, and a well established safety profile.

About Immune Design Corp.:

Immune Design Corp. is a privately held biotechnology company based in Seattle, WA. IDC brings together some of the worlds leaders in the field of molecular immunology to develop vaccines for the prevention and treatment of infectious and malignant disease. The company employs leading edge technologies to target and activate dendritic cells for effective antigen presentation to direct the desired immune response. For more information, go to www.immunedesign.com.

About MedImmune:

MedImmune, the worldwide biologics unit for AstraZeneca PLC (NYSE: AZN; LSE: AZN.L), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmunes website at www.medimmune.com.

Media Relations:

Immune Design Corp.

Cassie D. Ostrander (206) 826-7901

media@immunedesign.com



SOURCE Immune Design Corp.


Read at Xconomy
Read at BioSpace.com
Read at News Release

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES